Spots Global Cancer Trial Database for chronic lymphocytic leukaemia
Every month we try and update this database with for chronic lymphocytic leukaemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial | NCT01127542 | Chronic Lymphoc... | Lenalidomide | 18 Years - | The Christie NHS Foundation Trust | |
| A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | NCT01805375 | Indolent B-cell... Chronic Lymphoc... Waldenström Mac... | DI-B4 | 18 Years - | Cancer Research UK | |
| Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy | NCT06357754 | Non-Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... | Idecabtagene vi... Lisocabtagene m... | - | Bristol-Myers Squibb | |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | NCT04728893 | Hematologic Mal... Waldenstroms Ma... Non-Hodgkins Ly... Chronic Lymphoc... | Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | NCT04763083 | Chronic Lymphoc... Small Lymphocyt... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non-small Cell ... Malignant Melan... | NVG-111 | 18 Years - | NovalGen Ltd. | |
| Tissue Collection for Biomarkers Determining Resistance to Ibrutinib | NCT02267590 | Mantle Cell Lym... Chronic Lymphoc... | - | Royal Marsden NHS Foundation Trust | ||
| Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) | NCT00751296 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University Health Network, Toronto | |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | NCT03582098 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) | NCT00751296 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University Health Network, Toronto | |
| R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia | NCT00504491 | Chronic Lymphoc... Patients Resist... Patients Relaps... | Rituximab-CHOP-... | 18 Years - 70 Years | CABYC | |
| Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders | NCT01832597 | Chronic Lymphoc... | 18 Years - | Gruppo Italiano Studio Linfomi | ||
| Tissue Collection for Biomarkers Determining Resistance to Ibrutinib | NCT02267590 | Mantle Cell Lym... Chronic Lymphoc... | - | Royal Marsden NHS Foundation Trust | ||
| A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | NCT01805375 | Indolent B-cell... Chronic Lymphoc... Waldenström Mac... | DI-B4 | 18 Years - | Cancer Research UK | |
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | NCT01597219 | Hodgkin's Lymph... Non-Hodgkin's L... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Acquired Bone M... Other Haematolo... | Reduced intensi... Myeloablative h... | 16 Years - 70 Years | University College, London | |
| Tumor Registry of Lymphatic Neoplasia | NCT00889798 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | NCT01446900 | Chronic Lymphoc... Small Lymphocyt... | Rituximab Cladribine | 18 Years - | European Institute of Oncology | |
| RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial | NCT01127542 | Chronic Lymphoc... | Lenalidomide | 18 Years - | The Christie NHS Foundation Trust | |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | NCT04763083 | Chronic Lymphoc... Small Lymphocyt... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non-small Cell ... Malignant Melan... | NVG-111 | 18 Years - | NovalGen Ltd. | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | NCT01678430 | Chronic Lymphoc... | Ofatumumab Chlorambucil Bendamustine | 18 Years - | University of Liverpool | |
| A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma | NCT00457782 | Multiple Myelom... Chronic Lymphoc... B-cell Non-Hodg... | KW-2478 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | NCT02933320 | B-cell Lymphoma Chronic Lymphoc... Waldenström Mac... | BI-1206 single ... Combination of ... BI-1206 single ... Combination of ... | 18 Years - | Cancer Research UK | |
| Tumor Registry of Lymphatic Neoplasia | NCT00889798 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland | NCT03582098 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
